Literature DB >> 25806205

Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?

Sai-Hong Ignatius Ou1.   

Abstract

Entities:  

Year:  2013        PMID： 25806205      PMCID： PMC4367638          DOI： 10.3978/j.issn.2218-6751.2012.09.10

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Authors:  Ji-Youn Han; Keunchil Park; Sang-We Kim; Dae Ho Lee; Hyae Young Kim; Heung Tae Kim; Myung Ju Ahn; Tak Yun; Jin Seok Ahn; Cheolwon Suh; Jung-Shin Lee; Sung Jin Yoon; Jong Hee Han; Jae Won Lee; Sook Jung Jo; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

5.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

6.  Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Authors:  John R Johnson; Martin Cohen; Rajeshwari Sridhara; Yeh-Fong Chen; Gene M Williams; John Duan; Jogarao Gobburu; Brian Booth; Kimberly Benson; John Leighton; Li Shan Hsieh; Nallalerumal Chidambaram; Paul Zimmerman; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

7.  The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.

Authors:  Youngwook Kim; Jeonghun Ko; ZhengYun Cui; Amir Abolhoda; Jin Seok Ahn; Sai-Hong Ou; Myung-Ju Ahn; Keunchil Park
Journal:  Mol Cancer Ther       Date:  2012-01-06       Impact factor: 6.261

8.  Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  Suresh S Ramalingam; Fiona Blackhall; Maciej Krzakowski; Carlos H Barrios; Keunchil Park; Isabel Bover; Dae Seog Heo; Rafael Rosell; Denis C Talbot; Richard Frank; Stephen P Letrent; Ana Ruiz-Garcia; Ian Taylor; Jane Q Liang; Alicyn K Campbell; Joseph O'Connell; Michael Boyer
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

9.  United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.

Authors:  Martin H Cohen; Grant A Williams; Rajeshwari Sridhara; Gang Chen; W David McGuinn; David Morse; Sophia Abraham; Atiqur Rahman; Chenyi Liang; Richard Lostritto; Amy Baird; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

10.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.